Please assess the completion status of the following clinical trial:

Trial Title: Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of intrinsic pontine brain stem glioma within the past 30 days~  * Histologic confirmation not required provided the tumor has a pontine epicenter AND exhibits diffuse (rather than focal) involvement of ≥ 2/3 of the pons with or without extension to the adjacent medulla or midbrain\* NOTE: \*Brain stem tumors that do not meet these criteria must be histologically confirmed as grade III or IV malignant glioma~* Measurable disease by radiographic imaging~  * Post-operative MRI required within the past 30 days if patient had a biopsy or surgical resection~* No disseminated disease~* No neurofibromatosis type 1~PATIENT CHARACTERISTICS:~Age~* 3 to 21 at diagnosis~Performance status~* Lansky 50-100% OR~* Karnofsky 50-100%~Life expectancy~* At least 8 weeks~Hematopoietic~* Absolute neutrophil count ≥ 1,000/mm\^3~* Platelet count ≥ 100,000/mm\^3 (transfusion independent)~* Hemoglobin ≥ 10.0 g/dL (transfusion allowed)~Hepatic~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* ALT \< 2.5 times ULN~Renal~* Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR~* Creatinine based on age as follows:~  * No greater than 0.8 mg/dL (for patients ≤ 5 years of age)~ * No greater than 1.0 mg/dL (for patients 6 to 10 years of age)~ * No greater than 1.2 mg/dL (for patients 11 to 15 years of age)~ * No greater than 1.5 mg/dL (for patients over 15 years of age)~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Not severely somnolent or comatose~  * Central cortical neurotoxicity scale \< grade 3~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent immunomodulating agents~Chemotherapy~* No other concurrent anticancer chemotherapy~Endocrine therapy~* Concurrent corticosteroids allowed for neurological deficits related to the tumor~Radiotherapy~* No prior radiotherapy~Surgery~* See Disease Characteristics~* Prior biopsy or surgical resection for malignant brain stem glioma allowed~Other~* No other prior therapy for malignant brain stem glioma

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Dose Level I (0.5 mg/m^2) (Type: EXPERIMENTAL): Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n)
- Dose Level 2 (0.6 mg/m^2) (Type: EXPERIMENTAL): Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n.)

Based on this trial design, predict the completion outcome and termination type (if applicable).